On May 9, 2024, Eli Lilly and Company announced that it held its annual general meeting of shareholders on May 6, 2024, and declared voting results. Accordingly, a shareholder proposal from Trinity Health, requesting to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents was not approved.